Predictive Oncology Inc. (POAI) Dividend History

Company News

• UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

  Renovaro Inc. has received a ruling to expedite a trial in 2025 for a lawsuit it filed against Predictive Oncology Inc., seeking to enforce a binding merger agreement executed on January 1, 2025. Renovaro alleges that Predictive Oncology breached the agreement's exclusivity and good faith negotiation provisions.

  Benzinga

  Featured Companies: RENB
• Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

  Renovaro Inc. has filed a lawsuit against Predictive Oncology Inc. to enforce a binding merger agreement, alleging that Predictive Oncology breached the agreement's exclusivity and good faith negotiation provisions.

  Benzinga

  Featured Companies: RENB
• AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition

  Predictive Oncology leverages its vast biobank of tumor samples and drug response data to pursue AI-driven drug discovery, while Regeneron's acquisition of 23andMe highlights the value of genomic data in precision medicine.

  Benzinga

  Featured Companies: REGN
• Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update

  Predictive Oncology reported a loss of $10.8 million on $1.6 million in revenue for 2024. The company announced an agreement to merge with Renovaro, Inc. and the receipt of financing to integrate their AI/ML platform and laboratory capabilities.

  GlobeNewswire Inc.

  Featured Companies: RENB
• Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

  Predictive Oncology has successfully developed predictive models from 21 unique compounds provided by the University of Michigan's Natural Products Discovery Core. The models demonstrated strong tumor drug response across breast, colon, and ovary cancer types, outperforming a benchmark compound.

  GlobeNewswire Inc.